FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1.
Fiche du document
2009
- doi: 10.1083/jcb.200901104
- issn: 0021-9525
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1083/jcb.200901104
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/19398761
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1540-8140
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_15652A41591D3
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Speech--Transcription Language and languages--Transcription Transcribing TranscribingCiter ce document
C. Norrmén et al., « FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1. », Serveur académique Lausannois, ID : 10.1083/jcb.200901104
Métriques
Partage / Export
Résumé
The mechanisms of blood vessel maturation into distinct parts of the blood vasculature such as arteries, veins, and capillaries have been the subject of intense investigation over recent years. In contrast, our knowledge of lymphatic vessel maturation is still fragmentary. In this study, we provide a molecular and morphological characterization of the major steps in the maturation of the primary lymphatic capillary plexus into collecting lymphatic vessels during development and show that forkhead transcription factor Foxc2 controls this process. We further identify transcription factor NFATc1 as a novel regulator of lymphatic development and describe a previously unsuspected link between NFATc1 and Foxc2 in the regulation of lymphatic maturation. We also provide a genome-wide map of FOXC2-binding sites in lymphatic endothelial cells, identify a novel consensus FOXC2 sequence, and show that NFATc1 physically interacts with FOXC2-binding enhancers. As damage to collecting vessels is a major cause of lymphatic dysfunction in humans, our results suggest that FOXC2 and NFATc1 are potential targets for therapeutic intervention.